Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nejat Altintas (Samsun, Turkey), Nejat Altintas, Mustafa Erboga, Cevat Aktas. Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2015; 46: Suppl. 59, 927

Member's Comments

No comment yet.

Related content which might interest you: 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats? Source: International Congress 2016 – ILD pathogenesis Year: 2016 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Protective effects of Dengzhanshengmai capsules on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2014 – ILDs 3 Year: 2014